The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, Express Scripts, MedImpact Healthcare Systems and Navitus Health Solutions, th

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.

OptumRx, the group's pharmacy benefit manager, along with its two main peers, Express Scripts and CVS Caremark Rx, have pocketed an extra $7.3 billion over cost thanks to price gouging, according to the findings of a report by the Federal Trade Commission.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

CVS Health Corporation’s CVS Caremark, The Cigna Group’s CI Express Scripts, and UnitedHealth Group Incorporated’s UNH Optum Rx. This report comes at a time when insurers are grappling with ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,